When Constellation Pharmaceuticals first called to recruit venture capitalist Mark Goldsmith to be its chief executive in 2009, he was sceptical. Although Goldsmith was looking to change careers, he worried that the young biopharmaceutical company was heading into murky waters. The firm in Cambridge, Massachusetts, was focusing on epigenetics - the study of heritable changes in gene expression that are not due to changes in DNA sequence. It planned to create cancer treatments that correct the abnormal patterns of epigenetic DNA modifications seen in tumours. "I took some convincing," he says.
展开▼
